DR. GABRIEL LASALA DISCUSSES UNITED STATES’ FIRST FDA TRIAL USING A PATIENT’S OWN
STEM CELLS TO TREAT LOU GEHRIG’S DISEASE AT BATON ROUGE ALS SUPPORT GROUP
Covington, LA – U.S. Food and Drug Administration (FDA) has given TCA Cellular Therapy, LLC (TCA-CT) the green light to conduct their Phase I adult stem cell clinical trials to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), a fatal disease that afflicts approximately 30,000 Americans. This is the second FDA-approved protocol for the treatment of ALS using stem cells in the country; and the first using adult stem cells from the same patient. The aim of the Phase I study will assess safety.
Watch Dr. Lasala's presentation on TCA Cellular's ALS Trial Here!
Click Here for Video 1 Click Here for Video 2 Click Here for Video 3 Click Here for Video 4
TCA-CT currently has five FDA Cardiovascular Trials in progress utilizing adult stem cells, which has produced no adverse effects to date. Two of the trials will be entering Phase III, the final phase before marketability, later this year.
Dr. Lasala has been involved with research since 1981. As a practicing cardiologist, Lasala’s interest in stem cells peaked when he learned of a successful case study performed by a group of German doctors several years ago treating heart conditions using stem cells. Dr. Lasala started to search for a world expert in stem cells. After trips to Germany, China and Chile, Dr Lasala had a meeting with cell biologist Jose Minguell, PhD in Chile.
Until 2006, as the director the director of the department of Cellular Therapy at the Universidad de Chile in Santiago, Dr. Minguell joined TCA-CT with the US patent for isolating adult stem cells from a patient’s own bone marrow and the science to multiply the cells and utilize them in various medical applications,
About the Trial
Under the scientific guidance of cellular biologist, Jose J. Minguell, Ph.D., the adult stem cells will
be taken from the patient’s bone marrow in a simple outpatient procedure. The cells will then be
processed in TCA-CT’s GMP laboratory and administered to the patient by spinal tap in one of TCA-CT’s
Louisiana facilities.
Recruitment for trial patients will commence in the next few weeks. The company anticipates
moving into Phase II within a year.
About TCA Cellular Therapy
TCA Cellular Therapy, a privately-held company located in Covington, Louisiana has assembled
a team of neurologists, neurosurgeons, cell biologists, and pathologists to study some of the
most debilitating neurological diseases including ALS and Spinal Cord Injuries.
For more information, contact (985) 867-4860; www.tcacellulartherapy.com.
About ALS Association LA/MS Chapter
The ALSA Louisiana Chapter was founded in April, 2005 to serve the needs of those living with
Amyotrophic Lateral Sclerosis and their caregivers.
The ALS Association is the only national not-for-profit health organization dedicated solely to the fight against ALS. The Louisiana Chapter covers all the bases — research, patient and community services, public education, and advocacy — in providing help and hope to those facing the disease.
For more information on the ALS Association LA/MS Chapter, contact (225) 343-9880 or (800) 891-3746;
www.alsalams.org